Donor-Specific Regulatory T Cells Acquired from Tolerant Mice Bearing Cardiac Allograft Promote Mixed Chimerism and Prolong Intestinal Allograft Survival by Xiao-Fei Shen et al.
November 2016 | Volume 7 | Article 5111
Original research
published: 17 November 2016
doi: 10.3389/fimmu.2016.00511
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Brian Duncan Tait, 
Australian Red Cross Blood Service, 
Australia
Reviewed by: 
Bruce Milne Hall, 
University of New South Wales, 
Australia  
Luiza Guilherme, 
University of São Paulo, Brazil
*Correspondence:
Wen-Xian Guan  
guanwx-nju@hotmail.com; 
Jun-Feng Du  
dujf66@126.com
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 21 July 2016
Accepted: 02 November 2016
Published: 17 November 2016
Citation: 
Shen X-F, Jiang J-P, Yang J-J, 
Wang W-Z, Guan W-X and Du J-F 
(2016) Donor-Specific Regulatory T 
Cells Acquired from Tolerant Mice 
Bearing Cardiac Allograft Promote 
Mixed Chimerism and Prolong 
Intestinal Allograft Survival. 
Front. Immunol. 7:511. 
doi: 10.3389/fimmu.2016.00511
Donor-specific regulatory T cells 
acquired from Tolerant Mice Bearing 
cardiac allograft Promote Mixed 
chimerism and Prolong intestinal 
allograft survival
Xiao-Fei Shen1, Jin-Peng Jiang2, Jian-Jun Yang3, Wei-Zhong Wang3, Wen-Xian Guan1* and 
Jun-Feng Du4*
1 Department of General Surgery, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 
2 Department of Rehabilitation Medicine, PLA Army General Hospital, Beijing, China, 3 Division of Digestive Surgery, Xijing 
Hospital of Digestive Diseases, Fourth Military Medical University, Xi’an, China, 4 Department of General Surgery, PLA Army 
General Hospital, Beijing, China
The induction of donor-specific transplant tolerance has always been a central problem 
for small bowel transplantation (SBT), which is thought to be the best therapy for end-
stage bowel failure. With the development of new tolerance-inducing strategies, mixed 
chimerism induced by co-stimulation blockade has become most potent for tolerance 
of allografts, such as skin, kidney, and heart. However, a lack of clinically available 
co-stimulation blockers has hindered efficient application in humans. Furthermore, unlike 
those for other types of solid organ transplantation, strategies to induce robust mixed 
chimerism for intestinal allografts have not been fully developed. To improve current 
mixed chimerism induction protocols for future clinical application, we developed a new 
protocol using donor-specific regulatory T (Treg) cells from mice with heart allograft 
tolerance, immunosuppressive drugs which could be used clinically and low doses of 
irradiation. Our results demonstrated that donor-specific Treg cells acquired from toler-
ant mice after in vitro expansion generate stable chimerism and lead to acceptance of 
intestinal allograft. Increased intragraft Treg cells and clonal deletion contribute to the 
development of SBT tolerance.
Keywords: donor-specific regulatory T cells, mixed chimerism, transplantation tolerance, small bowel 
transplantation, bone marrow transplantation
inTrODUcTiOn
For patients with end-stage bowel failure, small bowel transplantation (SBT) is recognized as a defini-
tive therapy (1). However, the intestine carries the largest population of lymphoid cells of any trans-
planted solid organ, which are the least tolerogenic cells in any organ and they have the potential risk 
of inducing graft-versus-host reaction (2). Therefore, both acute and chronic rejection after SBT is 
still a great challenge to overcome, which leads to the inferior overall outcome of SBT when compared 
Abbreviations: (DS) Treg, (donor-specific) regulatory T cells; APC, antigen-presenting cell; BMC, bone marrow cells; BMDCs, 
bone marrow-derived dendritic cells; CFSE, carboxyflurescein diacetate succinmidyl ester; CTLA-4, cytotoxic T lymphocyte 
antigen-4; GM-CSF, granulocyte-macrophage colony-stimulating factor; ICOS, inducible co-stimulator; IFN-γ, interferon-γ; 
IL, interleukin; MLR, mixed lymphocytes reaction; SBT, small bowel transplantation; TNF-α, tumor necrosis factor-α.
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to that of other transplanted organs (3). Mixed hematopoietic 
chimerism, in which both donor and host stem cells contribute 
to hematopoiesis, could help to achieve potent donor-specific 
tolerance across full MHC barriers (4). Establishment of mixed 
chimerism through transplantation of donor bone marrow into 
recipients is one of the most promising strategies for inducing 
transplantation tolerance (5). Most of the chimerism-inducing 
protocols require the use of co-stimulation blockade agents (6). 
Recent results from experimental mouse studies based on co-
stimulation blockade induction of stable mixed chimerism are 
encouraging. However, translation of tolerance protocols from 
preclinical animal studies to the clinic is still a major challenge 
due to the lack of clinically available co-stimulation blockers (6). 
Regulatory T (Treg) cells have long been recognized to play a 
critical role in self-tolerance, but administration of Treg cells on 
their own does not induce robust immune tolerance across MHC 
barriers in immunocompetent hosts (7). Combining Treg cell 
therapy with co-stimulation blockade and rapamycin has been 
tested to promote full MHC-mismatched mixed chimerism, and 
the results are encouraging (8, 9). Furthermore, recipient donor-
specific Treg (DSTreg) cells are thought to be the most potent 
to promote mixed chimerism among all types of Treg cells (9). 
However, whether recipient DSTreg cells could lead to intestinal 
allograft acceptance after establishment of mixed chimerism has 
not been fully elucidated.
Our previous work (10) demonstrated that allograft accept-
ance can be established by donor-specific transfusion with com-
plete blockade of inducible co-stimulator (ICOS)/B7h signaling. 
Furthermore, this allograft acceptance was transferable and 
maintained by CD4+CD25+ T cells from recipient mice with long-
term allograft survival, and these Treg cells could be expanded 
in  vitro and exert donor-specific immune negative regulation. 
In the present study, a non-myeloablative protocol of combined 
transfusion of DSTreg cells and donor bone marrow, together with 
cytotoxic T lymphocyte antigen CTLA4Ig (abatacept, clinically 
available co-stimulation blocker) and rapamycin, was developed 
to establish mixed chimerism in lightly irradiated mice. We evalu-
ated the possibility of mixed chimerism to induce murine SBT 
tolerance and tried to develop new methods for clinical use.
MaTerials anD MeThODs
animals
Male mice of inbred strains BALB/c (H-2d), C57BL/6 (B6, H-2b), 
and C3H/HeJ (C3H, H-2k) aged 6–8 weeks were obtained from 
the Experimental Animal Center of the Fourth Military Medical 
University (Xi’an, China). All the animal experiments were 
carried out following the Guidelines for the Care and Use of 
Laboratory Animals of the Fourth Military Medical University 
and were approved by the ethical review committee of the Fourth 
Military Medical University.
Bone Marrow Preparation and  
Treatment regimens
Age-matched male mice received 3  Gy total body irradiation 
(Day −1), co-stimulation blockade with abatacept (0.5 mg/mouse, 
Day 2) (Orencia, Bristol-Myers Squibb Pharmaceuticals, Princeton, 
NJ, USA), and three doses of rapamycin (0.1mg/mouse, Days −1, 
0, and 1) (LC Laboratories, Woburn, MA, USA) were injected 
intravenously on day 0 with 2.0 × 107 unseparated bone marrow 
cells (BMCs) harvested from MHC-full mismatched BALB/c 
donors (8–12  weeks old), with or without expanded fresh 
Treg cells or expanded DSTreg cells (3 ×  106 per mouse). The 
preparation of BM of BALB/c mice was performed as previously 
described (11).
sBT and histological graft assessment
Heterotopic SBT was performed using a modified technique of 
Guo et al. (11). Briefly, about 5 cm of ileum was removed from 
donor mice on a vascular pedicle consisting of the superior 
mesenteric artery, abdominal aorta, and portal vein. The donor 
abdominal aorta was anastomosed end-to-side to the recipient 
infrarenal aorta and the donor portal vein to the recipient inferior 
vena cava. The proximal and distal ends of the intestinal graft were 
exteriorized stomas. Intestinal allografts were scored according to 
the following definitions: 0, no rejection; 1, scattered apoptotic 
crypt cells; 2, focal crypt destruction; and 3, mucosal ulceration 
with or without transmural necrosis (11).
skin grafting
Full-thickness tail skin from donor (BALB/c) and fully mis-
matched third-party (C3H) mice was grafted 100 days after SBT 
and visually inspected at short intervals thereafter. Grafts were 
considered to be rejected when <10% remained viable (12).
isolation of cD4+cD25+ Treg cells
CD4+CD25+ Treg cells were isolated as previously described (8). 
Fresh or DSTreg cells were isolated from spleen of naïve or toler-
ant B6 mice. CD4+CD25+ cells were purified by magnetic bead 
separation using negative selection for CD4+ and subsequent 
positive selection for CD25+ by incubating CD4+ enriched cells 
with phycoerythrin (PE)-conjugated α-CD25 (PC61) followed by 
α-PE microbeads (CD4+CD25+ Regulatory T-cell Isolation Kit; 
MiltenyiBiotec, Bergisch Gladbach, Germany) (13). The purity 
of separated cells was >90%.
generation of Dendritic cells
Bone marrow-derived dendritic cells (BMDCs) were induced in 
the medium of 4 ml complete RPMI 1640, by adding 20 ng/ml 
granulocyte-macrophage colony-stimulating factor (GM-CSF). 
On days 3 and 5, the culture medium was replaced by fresh 
medium with GM-CSF (20 ng/ml). On day 6, cells were addition-
ally treated with 1 μg/ml lipopolysaccharide for 24 h to further 
induce the maturation of DC. Loosely adherent cells and those 
in the culture supernatant were harvested by gentle washing with 
PBS for further use.
Treg-cell Proliferation assay
Sorted CD4+CD8−CD25+ T cells (5 × 104) from naïve and tolerant 
B6 mice bearing cardiac grafts were cultured for 14 days at 37°C in 
5% CO2 with 2 × 105 BALB/c BMDCs in the presence or absence 
of interleukin (IL)-2 (1000 U/ml) and rapamycin (100 nM), alone 
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or in combination. In some experiments, T cells were prelabeled 
with a solution of 5 mM carboxyflurescein diacetate succinmidyl 
ester (CFSE; Invitrogen, Carlsbad, CA, USA), followed by culture 
for 7 days with various stimuli. CFSE dilution was analyzed on a 
Beckman Coulter Epics XL.
cD4+cD25+ Treg cell immunosuppression 
assay
Mixed lymphocytes reaction (MLR) was used to assess the sup-
pressive activity of CD4+ CD25+ Treg cells as previously described 
(14, 15). Briefly, CD4+CD8−CD25+ and CD4+CD8−CD25− T cells 
with ratios ranged from 1:1 to 1:16 were cultured for 72  h in 
96-well flat-bottomed plates with anti-CD3 (5 μg/ml) and irradi-
ated splenocytes (APCs). After 3 days in culture, 3H-thymidine 
was added to each well for an additional 18  h. 3H-thymidine 
incorporation was measured on a β-scintillation counter (15).
Mlr in Mixed chimeras
MLRs in chimeras were performed as described previously (12, 
16). Briefly, 4 ×  105 responder splenocytes were incubated in 
triplicate with 4 × 105 irradiated (30 Gy) stimulator cells of either 
B6 (recipient), BALB/c (donor), or C3H (third party) origin 
or with medium only. After 72 h incubation, cells were pulsed 
with [3H]-thymidine (Amersham Biosciences, Little Chalfont, 
Bucks, UK) for 18  h. Incorporated radioactivity was measured 
using scintillation fluid in a β counter. Stimulation indices were 
calculated in relation to medium controls.
isolation of lamina Propria lymphocytes 
in the small intestine
Isolation of lamina propria cells from the small intestine was 
performed as previously described (17). The whole transplanted 
small intestine was cut into pieces 0.5 cm in length and shaken 
twice at 250  rpm for 30  min at 37°C in Hanks’ Balanced Salt 
Solution (Life Technologies) supplemented with 5% (v/v) fetal 
bovine serum (CellGro) containing 2 mM EDTA. The remaining 
intestinal tissues were washed and shaken for 30  min at 37°C 
in RPMI 1640 plus 5% (v/v) fetal bovine serum and type IV 
collagenase (1  mg/ml; Sigma). Cell suspensions were enriched 
by centrifugation at room temperature at 500  g for 20  min in 
40%/70% Percoll (GE Healthcare) in RPMI 1640. The interface 
layer cells were used for further analysis.
Flow cytometry, Monoclonal antibodies, 
and reagents
Peripheral blood was collected, the red cells were lysed, and the 
remaining cells washed with a whole blood lysis kit (R&D Systems, 
Minneapolis, MN, USA). Peripheral blood leukocytes were stained 
with fluorochrome-conjugated anti-CD3, anti-CD11b, anti-GR1, 
anti-B220, anti-H-2Kb, anti-Vb11, anti-H-2Kd, anti-Vb8.1/8.2, 
anti-Vb5.1/5.2 (PharMingen, San Diego, CA, USA), anti-CD4, 
anti-CD8 (Caltag, Burlingame, CA, USA), or immunoglobulin 
isotype controls (PharMingen, Caltag). Donor chimerism was 
expressed as a percentage that was calculated using the following 
formula: (H-2Kd+ cells/total gated cells) × 100 (11).
The following monoclonal antibodies (mAbs) were purchased 
from BD Biosciences PharMingen: anti-mCD4-APC-CY7, 
anti-mCD45RB-PE, anti-mCD44-PE, anti-mCD62L-PE, anti-
mCTLA4-PE, anti-mGITR-PE. Anti-mCD4-FITC, anti-mCD8-
PE, anti-mCD4-APC, anti-mFoxp3-PE, and anti-mCD25-PE-CY5 
were purchased from eBioscience.
elisa for intestinal inflammatory 
cytokines
Small intestine cytokines were measured with a mouse-specific 
cytokines ELISA kit (eBioscience, San Diego, CA, USA). Tissues 
were homogenized in ice-cold RIPA buffer [150  mM NaCl, 
50 mM Tris–HCl, 1 mM EDTA, and 1% Triton-X (pH 7.4)], and 
samples processed for mouse-specific ELISA kits.
statistical analysis
Survival data were analyzed using the Kaplan–Meier method 
with the log-rank test to verify the significance of the difference 
in survival between the groups. Data are presented as mean ± SD. 
Student’s unpaired t-test for comparison of means was used to 
compare groups. P <  0.05 was considered to be of significant 
difference.
resUlTs
expansion of Fresh and Donor-specific 
cD4+cD25+ Treg cells
Previously, we have shown that DSTreg cells from tolerant B6 
mice bearing cardiac grafts induce cardiac graft acceptance in 
irradiated B6 mice (Figure  1A) (10). To expand CD4+CD25+ 
Treg cells, we first purified single splenocytes from naïve or toler-
ant B6 mice using a CD4+CD25+ Regulatory T-cell Isolation Kit 
(MiltenyiBiotec) (18). The purity of separated cells was confirmed 
to be >90% (Figure 1C). Numerous in vitro and in vivo studies 
have suggested the critical role of rapamycin in expanding natu-
rally occurring CD4+CD25+Foxp3+ Treg cells that are normally 
found in the naïve splenic CD4+ T-cell compartment, as well as in 
maintaining their suppressive function in vitro (19–21). We used 
similar culture conditions with some modification. After 14 days 
stimulation, we found that DSTreg and fresh Treg cells could be 
expanded stably in vitro, and the combination of rapamycin plus 
IL-2 resulted in greatest expansion of fresh CD4+CD25+ Treg cells 
(23.7 ± 1.8-fold) and DSTreg cells (31.5 ± 2.1-fold) (Figure 1B). 
The purity of the expanded cells was >95% (Figure  1C). 
Furthermore, DSTreg cells proliferated more efficiently than fresh 
Treg cells in response to IL-2 and rapamycin (Figure 1B). When 
analyzing the expression of surface markers by flow cytometry, 
DSTreg cells from tolerant mice expressed equal levels of CD62L, 
CD44, CTLA-4, and GITR as fresh Treg cells derived from naïve 
mice did (data not shown). Ex vivo fresh Treg and DSTreg cells 
were also assessed for suppression in MLR assays. Expanded 
DSTreg cells displayed a more powerful inhibitory function than 
fresh Treg, expanded fresh Treg, and DSTreg cells (Figure 1D). 
We also confirmed that the enhanced suppressive function of 
expanded DSTreg cells was donor specific (Figure 1E). Therefore, 
we established a method that could expand DSTreg cells in vitro.
FigUre 1 | In vitro expansion of cD4+cD25+ Treg cells and comparison with immunosuppressive function of expanded Treg cells. (a) Schematic 
drawing of the protocol to acquire DSTreg cells from tolerant mice bearing heart allografts. (B) Fresh CD4+CD25+ T cells and DSTreg cells (5 × 104) were separated 
by magnetic bead sorting and cultivated in the presence or absence of IL-2 (1000 U/ml), splenic donor APCs (105 cells), and rapamycin (100 nM), or in combination 
for 7 days at 37°C in 5% CO2. DSTreg cells proliferated more efficiently in response to the indicated stimulation compared with fresh CD4+CD25+ T cells as 
determined by CFSE-labeled cell proliferation assay in vitro. (c) Representative FACS blot depicting Foxp3 expression among CD4+ T cells from naïve or tolerant 
mice after in vitro cultivation. (D) Fresh CD4+CD25+ T cells, ex vivo-expanded fresh CD4+CD25+ T cells, DSTreg cells from tolerant mice, and ex vivo-expanded 
DSTreg cells were assayed for suppressive activity in response to BALB/c spleen cells and third-party spleen cells (C3H) (e). All curves are expressed as percentage 
of control MLR and represent the combined average values of five individual experiments. Data are shown as mean ± SD (n = 3–5 mice/group). One representative 
of at least two independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.005 compared among the indicated groups.
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Donor-specific Treg cell Treatment leads 
to Multilineage Mixed chimerism
Next, we investigated the potency of expanded DSTreg and 
expanded fresh Treg cells for induction of chimerism and toler-
ance. Under the cover of co-stimulation blockade with abatacept, 
a low dose of 3 Gy irradiation and three doses of rapamycin, B6 
mice received a conventional dose of fully mismatched BALB/c 
BM (2 × 107 cells per mouse), together with different numbers 
of expanded DSTreg or fresh Treg cells (105, 5 × 105, 106, 2 × 106, 
or 3 ×  106 per mouse). Most recipients treated with Treg cells 
developed mixed chimerism, whereas no chimerism was detected 
without Treg cell treatment 4  weeks after BMT (Figure  2A). 
BMT recipients treated with expanded DSTreg cells displayed 
higher chimerism rates than those with expanded fresh Treg 
cells, and cell numbers could even be reduced to 5 × 105 cells/
mouse (Figure 2A). Chimerism levels in recipients treated with 
expanded DSTreg cells were also significantly higher than those in 
recipients treated with expanded fresh Treg cells (Figures 2B,C). 
The best induction of stable mixed chimerism was achieved 
with injection of 3 × 106 cells/mouse (Figure 2C); therefore, we 
used this number of cells for subsequent experiments. We also 
discovered that BMT recipients treated with expanded DSTreg 
cells achieved substantial levels of T cells, B cells, granulocytes, 
and macrophages chimerism at indicated time points post-BMT, 
while the levels of chimerism in recipients treated with expanded 
fresh Treg cells were relatively low (Figure 2D). Therefore, these 
results suggest that expanded DSTreg cells were more potent 
than expanded fresh Treg cells in the induction of hematopoietic 
chimerism.
clinical Manifestation and  
graft survival rates
After the establishment of BM chimerism, we further investi-
gated whether mixed chimerism induced by Treg cells could 
promote intestinal allograft tolerance. SBT was performed 
4 weeks after BMT. The intestinal grafts in the allogeneic group 
were all rejected within 14 days. Intestinal grafts in recipients 
that received BM cell infusion showed similar survival rates 
to those in the allogeneic group (Figure 3A), while intestinal 
grafts in the BM cells + expanded fresh Treg cells group sur-
vived for an extended period of 50 days after transplantation 
(Figure 3A). Intestinal grafts in the chimera recipients induced 
FigUre 2 | DsTreg cell treatment together with low-dose irradiation leads to multilineage mixed chimerism. (a) Groups of C57BL/6J mice were 
transplantated with fully mismatched BALB/c BM cells (2 × 107) under low doses of irradiation (3 Gy total body irradiation at day −1), co-stimulation blockade with 
abatacept (CTLA-4-Ig) (0.05 mg at day 2), and three doses of rapamycin (0.1 mg at days 1, 0, and 2) were additionally treated with or without different numbers of 
expanded DSTreg cells, or expanded fresh Treg cells at day 0. Percentages of successfully induced chimeras are shown. Chimerism was considered to be 
established if donor cells were detectable by flow cytometry within both the myeloid lineage and at least one lymphoid lineage for the duration of follow-up. (B) 
Hematopoietic reconstitution was assessed at 3 weeks after BMT. Values for individual mice are shown; bars indicated means. (c) Typical FACS plots of H-2Kb 
(recipient) versus H-2Kd (donor) staining were carried out 3 weeks after BMT. (D) Donor (H-2Dd) chimerism among leukocytes was assessed by flow cytometry of 
peripheral blood at multiple time points (2, 4, 8, 12, 16, 20, and 24 weeks post-BMT) and is shown as mean percentage. *P < 0.05, **P < 0.01, ***P < 0.005 
compared among the indicated groups.
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by expanded DSTreg cells survived for the longest period, and 
more than half of the grafts survived for the duration of follow-
up, without the presence of both acute and chronic rejection 
(Figure 3A). When comparing the histological results among 
each group, chimeras induced through DSTreg cell infusion 
demonstrated viable and best-preserved structure of mucosa 
and villi (Figure 3B). The stoma in this group also had good 
structure. The relative rejection score was also significantly 
lower in chimeras induced by BM and DSTreg cell treatment 
(Figure 3C).
The main factors controlling organ rejection are the balance 
between cellular immune responses mediated by T-helper cells 
that produce numerous proinflammatory cytokines and inhibi-
tory cytokines. Thus, the grafts concentrations of inflammatory-
response-related Th1/Th2 and Th17/Treg cytokines were also 
assayed with ELISA. The concentrations of tumor necrosis factor 
(TNF)-α, IL-17A, IL-23, and interferon (IFN)-γ all increased 
gradually in the allogeneic control group (Figure 3D). Compared 
to the allogeneic control group, the concentrations of IL-23, 
IFN-γ, and IL-17A in the grafts of chimeras were significantly 
lower on days 5, 7, and 11 than those in the allogeneic control 
group (Figure 3D). The concentrations of inhibitory cytokines 
transforming growth factor-β and IL-10 were significantly 
higher in the chimera group than in the allogeneic group on days 
5, 7, and 11 (Figure 3E), and the levels of these two inhibitory 
cytokines were higher in the BM + DSTreg cell group than in the 
BMC + fresh Treg cells group (Figure 3E). These results suggest 
that recipients treated with BMC + DSTreg cells can better accept 
small bowel allografts, with low levels of inflammatory response 
and acute rejection.
FigUre 3 | chimeras induced by DsTreg cells developed full donor-specific intestine allograft tolerance, and tolerant chimeras displayed hypo-
inflammatory responses in the intestinal allografts. (a) Graft survival of intestinal allografts. (B) Representative hematoxylin-and-eosin-stained (original 
magnification: ×100) sections of intestinal allografts from recipients treated with low-dose irradiation (3 Gy) and BM cells, with or without expanded DSTreg cells, and 
expanded fresh Treg cells (14 days post-SBT). (c) Allografts were assigned an acute rejection score by a blinded pathologist. (D,e) Cytokine concentrations in the 
recipient intestinal allografts were measured by ELISA on days 1, 5, 7, and 11 after SBT. Data are shown as mean ± SD (n = 4–7). One representative of at least two 
independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.005 compared among the indicated groups.
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increased infiltration of cD4+Foxp3+ Treg 
cells in small Bowel grafts and Deletion 
of Donor-reactive T cells of Mixed 
chimeras induced by BM and DsTreg cell 
infusion
To assess tolerance in these fresh Treg and DSTreg induced 
chimeras, in  vitro MLR assays were performed to evaluate 
self-reactivity, donor-reactivity, and third-party reactivity. 
In chimeras treated with Treg cells, responsiveness toward 
the donor was almost reduced to the level of self-reactivity 
(Figure  4A), whereas third-party reactivity was preserved 
(Figure  4A). CD4+Foxp3+ Treg cells have been implicated to 
play a crucial role in homeostasis of intestinal immunity (18, 
22, 23), and dysregulation of the number and function of Treg 
cells contributes to the development of intestinal transplanta-
tion rejection (24, 25). Previous results have also suggested 
higher levels of inhibitory cytokines relative to Treg cells in 
recipients treated with expanded DSTreg cells. Therefore, we 
obtained intestinal grafts and directly assessed the infiltration 
of CD4+Foxp3+ Treg cells as previously described (17). The 
percentage of infiltrating CD4+Foxp3+ Treg cells was signifi-
cantly higher in grafts of chimeras treated with BM + expanded 
DSTreg cells compared to those of chimeras treated with BM 
cells only or BM +  expanded fresh Treg cells (Figures 4B,C). 
Although the percentage of Foxp3+ Treg cells in CD4+ T cells 
in the spleen of recipients treated with expanded DSTreg cells 
was higher than that in recipients treated with expanded fresh 
Treg cells, no significant difference was discovered (Figure 4D). 
The frequency of CD4+Foxp3+ Treg cells in peripheral blood is 
FigUre 4 | regulatory mechanism and clonal deletion contribute to intestinal allograft acceptance in chimeras treated with expanded DsTreg cells. 
(a) Donor reactivity was assessed in MLRs at 8 weeks post-BMT. Donor-specific responses and third-party reactivity were measured in each group. Simulation 
indices were calculated by dividing the mean cpm from responses against recipient (C57BL/6J), donor (BALB/c), or third-party (C3H) stimulator cells by mean 
background cpm (i.e., cpm with no stimulator population). The percentage of CD4+Foxp3+ cells in recipient allografts (B,c), spleen (D), and peripheral blood (e) was 
measured by multicolor flow cytometry on day 14 after SBT. (F) Deletion of donor-reactive T cells in chimeras was shown by assessing percentages of Vβ11, Vβ5, 
and Vβ8. Multicolor flow cytometry was used for measurement in selected mice at 8 weeks post-BMT. Chimeras treated with expanded DSTreg cells showed 
significant peripheral and central clonal deletion among donor-reactive T cells, as measured by percentage of Vβ11 and Vβ5 (but not Vβ8). Data are shown as 
mean ± SD (n = 4–6). One representative of at least three independent experiments is shown. *P < 0.05, **P < 0.01, ***P < 0.005 compared among the indicated 
groups.
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negatively correlated with severity of graft versus host diseases 
in humans (26) and is also regarded as a biomarker for hemat-
opoietic cell transplantation outcomes (27). Similar results were 
also obtained in our model (Figure 4E).
Mixed chimerism was induced in our model and chimeric 
recipients displayed hyporesponsiveness to donor antigens; 
therefore, deletion of intrathymic and peripheral donor-
reactive T cells might also underlie the lack of responsiveness to 
donor antigens. To test this hypothesis, we examined the levels 
of certain Vβ subunits within the T-cell receptor repertories. 
The frequencies of Vβ11+ and Vβ5+ peripheral CD4+ T cells 
were low in chimeras treated with expanded DSTreg cells, 
which suggested the establishment of peripheral clonal dele-
tion, while it was incomplete in chimeras with BM cells, low-
dose irradiation, and expanded fresh Treg cells (Figure  4F). 
No deletion was seen in recipients without Treg cell treatment 
(Figure 4F). Furthermore, significant intrathymic deletion was 
also achieved in recipients treated with expanded DSTreg cells 
(Figure 4F).
Donor-specific skin graft acceptance in 
Mixed chimeras receiving BM and DsTreg 
cell infusion, and Maintenance of normal 
immune response to Third-Party grafts
To determine whether or not tolerance was donor-specific in 
recipients treated with DSTreg cells after SBT, skin transplanta-
tion was performed 100 days after SBT. Mice receiving DSTreg 
cells that did not accept small bowel grafts rejected both BALB/c 
and C3H skin grafts within 14 days, while mice achieving small 
bowel grafts permanently also accepted BALB/c skin grafts per-
manently. These mice also rejected C3H skin grafts, which further 
showed that mice that accepted small bowel grafts achieved 
donor-specific transplantation tolerance (Figure 5).
FigUre 5 | Mixed chimeras of DsTreg cell infusion group received 
donor-specific skin grafts and retained normal immune response to 
third-party grafts. Skin transplantation was performed 100 days after SBT 
in recipients (C57BL/6) treated with DSTreg cells, and survival curve of skin 
grafts from donor-specific Balb/c mice and C3H mice was shown. 
Donor-specific Balb/c skin grafts survived in most chimeras, whereas C3H 
skin was rejected. *P < 0.05, **P < 0.01, ***P < 0.005 compared among the 
indicated groups.
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DiscUssiOn
We (28) and others (23, 29) have suggested the critical role 
of Treg cells in maintaining intestinal homeostasis, and bet-
ter control of the number and function of Treg cells in GALT, 
especially in the intestine, might be a promising prospect for 
the acceptance of intestinal allografts. How to maintain long-
term DSTreg cells and/or expand them in vivo has always been 
a central problem in immune tolerance, and isolating sufficient 
numbers of Treg cells for in vivo use is also a significant clinical 
challenge (21). Previously, we have shown that donor-specific 
transfusion with complete blockade of ICOS/B7h signaling can 
achieve immune tolerance (10). Furthermore, this allograft 
acceptance is transferable and mediated by CD4+CD25+Foxp3+ 
T cells from recipient mice. To acquire large numbers of these 
DSTreg cells for further use, we tried to expand the cells in vitro. 
Mature DCs have been suggested to be the most potent APCs 
to expand antigen-specific Treg cells in the presence of high-
dose IL-2 (30). Since spleen cells are a mixture of many cell 
types with only 1–1.5% being DCs, among which the majority 
are in an immature state, we used BMDCs as donor-specific 
APCs to stimulate Treg cells, with or without rapamycin or 
IL-2, alone or in combination. After 2  weeks of co-culture, 
our results clearly showed that BMDCs could expand these 
DSTreg cells with potent suppressive function in  vitro in the 
presence of IL-2 and rapamycin, which is consistent with 
other in vitro and in vivo results (19–21). In vitro results also 
demonstrated that these expanded DSTreg cells displayed more 
powerful immunosuppressive function. However, it has been 
shown that infusion of DSTreg cells alone only delays CD4+ 
T-cell-mediated skin graft rejection and CD8+ T-cell-mediated 
allograft rejection (11, 31, 32), and results from highly immu-
nogenic organ transplantation models are still frustrating (11). 
We (4) also acquired similar results in SBT, which drove us 
to seek better strategies for immune tolerance in SBT. Studies 
have also suggested that rodent models for tolerance through 
mixed chimerism are among the most robust, which might be 
the best candidate for clinical trials (8, 33, 34). Recently, long-
term stable kidney allograft survival without maintenance 
immunosuppression was also achieved by infusion of BM cells 
(35). Therefore, chimerism might be a promising strategy for 
intestinal transplantation.
Various mixed chimerism protocols have been developed 
including the use of immunosuppressive drugs, co-stimulation 
blockade (36, 37), Foxp3+ Treg cell application (8, 38), and T-cell 
depletion (11, 39). Among all these, strategies based on the use 
of co-stimulation blockade are the most potent at inducing 
mixed chimerism (6). However, there are few reports on pro-
tocols for promoting stable intestinal allograft acceptance. Guo 
et al. have conducted a series of studies on biological agents that 
delay intestinal acute rejection and found that chimerism with 
anti-CD40L mAb, CTLA4-Ig, donor BM, and busulfan prolong 
intestinal allograft survival (11). However, their strategy still 
failed to achieve long-term survival of intestinal allografts with 
different levels of chimerism and persistence of donor-reactive 
T cells in recipients. Furthermore, they could not identify Treg 
cells in chimeric recipients bearing intestinal allografts, which 
suggest the absence of a regulatory mechanism in this model. 
Recently, combining Treg therapy with non-cytoreductive 
BMT has been suggested to promote acceptance of heart 
grafts in mice (12). Although this kind of Treg-cell-induced 
strategy achieved immune tolerance, the levels of chimerism 
observed were low and depletion of donor-reactive T cells was 
also incomplete, which might not be suitable for application to 
immunogenic organs like the intestine (8, 12). Furthermore, 
in addition to tolerization of intrathymic newly developing 
T-cell repertoire, pre-existing mature donor-reactive T cells 
also need to be tolerized through peripheral mechanisms in 
such protocols (9).
In our study, we found that DSTreg cells from tolerant mice 
stably induced mixed chimerism and further promoted the 
intestinal allograft acceptance. The percentage of Treg cells in 
the intestine was also significantly high in the DSTreg-cell-
induced chimeras, which might have contributed to the low 
levels of inflammatory response. Similar results were found 
in peripheral blood, which strongly suggests achievement 
of immune tolerance in these recipient mice. Besides, clonal 
deletion is considered the backbone of tolerance through 
chimerism (40), and most groups investigating tolerance 
associated with chimerism-inducing strategies have reported 
deletion of donor-reactive CD4+ T cells (11). We also observed 
significant deletion of Vβ5+ and Vβ11+ MMTV-reactive CD4+ 
and CD8+ T cells in DSTreg-cell-induced chimeras. Therefore, 
clonal deletion and regulatory mechanisms both contribute 
to promote allograft acceptance in our study. We also further 
demonstrated that immune tolerance induced in our model 
was donor specific.
In conclusion, we have developed a new mixed-chimerism-
inducing protocol using the DSTreg cells acquired from tolerant 
mice bearing heart allografts and have promoted the acceptance 
of intestinal allografts. These results underlie the clinical poten-
tial of Treg-cell-based chimerism and subsequent prevention 
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of solid organ transplantation rejection that is highly immu-
nogenic. Further studies on determining the origin (donor or 
recipient) and migration pattern of Treg cells in these tolerant 
mice bearing intestinal allografts are needed so that they can be 
used clinically.
aUThOr cOnTriBUTiOns
J-FD and W-XG conceived and designed the experiments; X-FS 
and J-PJ performed the experiments; J-JY and W-ZW analyzed 
the data; J-PJ, X-FS, and J-JY contributed reagents/materials/
analysis tools; J-FD and X-FS wrote the paper.
acKnOWleDgMenTs
We thank Ying Xing and Qiang He for their excellent technical 
assistance.
FUnDing
This work was supported by National Natural Science Foundation 
of China (No. 81000189, 81571563, J-FD, and 81500432, X-FS), 
China Postdoctoral Science Foundation (No.2014M552695, 
J-FD), PLA Youth Culturing Project of Medical Science 
(No.14QNP009, J-FD), and the Fundamental Research Funds for 
the Central Universities (No. 021414380106, X-FS).
reFerences
1. Fishbein TM. Intestinal transplantation. N Engl J Med (2009) 361:998–1008. 
doi:10.1056/NEJMra0804605 
2. von Websky MW, Kalff JC, Schafer N. Current knowledge on regulation and 
impairment of motility after intestinal transplantation. Curr Opin Organ 
Transplant (2015) 20:303–7. doi:10.1097/MOT.0000000000000190 
3. Berger M, Zeevi A, Farmer DG, Abu-Elmagd KM. Immunologic challenges 
in small bowel transplantation. Am J Transplant (2012) 12(Suppl 4):S2–8. 
doi:10.1111/j.1600-6143.2012.04332.x 
4. Du JF, Li SY, Yu B, Bai X. Treg-based therapy and mixed chimerism in small 
intestinal transplantation: does Treg +BMT equal intestine allograft tolerance? 
Med Hypotheses (2011) 76:77–8. doi:10.1016/j.mehy.2010.08.035 
5. Kawai T, Cosimi AB, Spitzer TR, Tolkoff-Rubin N, Suthanthiran M, 
Saidman SL, et  al. HLA-mismatched renal transplantation without mainte-
nance immunosuppression. N Engl J Med (2008) 358:353–61. doi:10.1056/
NEJMoa071074 
6. Pilat N, Hock K, Wekerle T. Mixed chimerism through donor bone 
marrow transplantation: a tolerogenic cell therapy for application in organ 
transplantation. Curr Opin Organ Transplant (2012) 17:63–70. doi:10.1097/
MOT.0b013e32834ee68b 
7. Joffre O, Santolaria T, Calise D, Al Saati T, Hudrisier D, Romagnoli P, et al. 
Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ 
regulatory T lymphocytes. Nat Med (2008) 14:88–92. doi:10.1038/nm1688 
8. Pilat N, Baranyi U, Klaus C, Jaeckel E, Mpofu N, Wrba F, et  al. Treg-
therapy allows mixed chimerism and transplantation tolerance with-
out cytoreductive conditioning. Am J Transplant (2010) 10:751–62. 
doi:10.1111/j.1600-6143.2010.03018.x 
9. Pilat N, Wekerle T. Mechanistic and therapeutic role of regulatory T cells in 
tolerance through mixed chimerism. Curr Opin Organ Transplant (2010) 
15:725–30. doi:10.1097/MOT.0b013e3283401755 
10. Du JF, Wang C, Wang WZ, Li MB, Liang HL, Guan WX. Transferable 
cardiac allograft acceptance induced by transfusion of donor B cells with 
impaired inducible costimulator/B7h allorecognition. Transplant Proc (2009) 
41:1840–3. doi:10.1016/j.transproceed.2009.01.106 
11. Guo Z, Wang J, Dong Y, Adams AB, Shirasugi N, Kim O, et al. Long-term 
survival of intestinal allografts induced by costimulation blockade, busul-
fan and donor bone marrow infusion. Am J Transplant (2003) 3:1091–8. 
doi:10.1034/j.1600-6143.2003.00127.x 
12. Pilat N, Farkas AM, Mahr B, Schwarz C, Unger L, Hock K, et al. T-regulatory 
cell treatment prevents chronic rejection of heart allografts in a murine mixed 
chimerism model. J Heart Lung Transplant (2014) 33:429–37. doi:10.1016/j.
healun.2013.11.004 
13. Mahr B, Unger L, Hock K, Pilat N, Baranyi U, Schwarz C, et  al. IL-2/
alpha-IL-2 complex treatment cannot be substituted for the adoptive transfer 
of regulatory T cells to promote bone marrow engraftment. PLoS One (2016) 
11(1):e0146245. doi:10.1371/journal.pone.0146245 
14. Wang H, Zhao L, Sun Z, Sun L, Zhang B, Zhao Y. A potential side effect of 
cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. 
Transplantation (2006) 82:1484–92. doi:10.1097/01.tp.0000246312.89689.17 
15. Xia GL, Kovochich M, Truitt RL, Johnson BD. Tracking ex vivo-expanded 
CD4(+)CD25(+) and CD8(+)CD25(+) regulatory T cells after infusion to 
prevent donor lymphocyte infusion-induced lethal acute graft-versus-host 
disease. Biol Blood Marrow Transplant (2004) 10:748–60. doi:10.1016/ 
j.bbmt.2004.07.004 
16. Wekerle T, Kurtz J, Ito H, Ronquillo JV, Dong V, Zhao G, et al. Allogeneic bone 
marrow transplantation with co-stimulatory blockade induces macrochime-
rism and tolerance without cytoreductive host treatment. Nat Med (2000) 
6:464–9. doi:10.1038/74731 
17. Du J, Shen X, Zhao Y, Hu X, Sun B, Guan W, et al. Wip1-deficient neutrophils 
significantly promote intestinal ischemia/reperfusion injury in mice. Curr Mol 
Med (2015) 15:100–8. doi:10.2174/1566524015666150114122929 
18. Veenbergen S, Samsom JN. Maintenance of small intestinal and colonic 
tolerance by IL-10-producing regulatory T cell subsets. Curr Opin Immunol 
(2012) 24:269–76. doi:10.1016/j.coi.2012.03.004 
19. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands 
CD4(+)CD25(+)FoxP3(+) regulatory T cells. Blood (2005) 105:4743–8. 
doi:10.1182/blood-2004-10-3932 
20. Ogino H, Nakamura K, Iwasa T, Ihara E, Akiho H, Motomura Y, et  al. 
Regulatory T cells expanded by rapamycin in  vitro suppress colitis in an 
experimental mouse model. J Gastroenterol (2012) 47:366–76. doi:10.1007/
s00535-011-0502-y 
21. Shin HJ, Baker J, Leveson-Gower DB, Smith AT, Sega EI, Negrin RS. 
Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated 
with increased expansion of donor type CD4(+)CD25(+)Foxp3(+) regula-
tory T cells. Blood (2011) 118:2342–50. doi:10.1182/blood-2010-10-313684 
22. Haghikia A, Jorg S, Duscha A, Berg J, Manzel A, Waschbisch A, et al. Dietary 
fatty acids directly impact central nervous system autoimmunity via the small 
intestine. Immunity (2015) 43:817–29. doi:10.1016/j.immuni.2015.09.007 
23. Kim KS, Hong SW, Han D, Yi J, Jung J, Yang BG, et al. Dietary antigens limit 
mucosal immunity by inducing regulatory T cells in the small intestine. 
Science (2016) 351:858–63. doi:10.1126/science.aac5560 
24. Xie FT, Cao JS, Zhao J, Yu Y, Qi F, Dai XC. IDO expressing dendritic cells sup-
press allograft rejection of small bowel transplantation in mice by expansion 
of Foxp3+ regulatory T cells. Transpl Immunol (2015) 33:69–77. doi:10.1016/j.
trim.2015.05.003 
25. Rieger K, Loddenkemper C, Maul J, Fietz T, Wolff D, Terpe H, et al. Mucosal 
FOXP3+ regulatory T cells are numerically deficient in acute and chronic 
GvHD. Blood (2006) 107:1717–23. doi:10.1182/blood-2005-06-2529 
26. Engelhardt BG, Jagasia M, Savani BN, Bratcher NL, Greer JP, Jiang A, et al. 
Regulatory T cell expression of CLA or alpha(4)beta(7) and skin or gut acute 
GVHD outcomes. Bone Marrow Transplant (2011) 46:436–42. doi:10.1038/
bmt.2010.127 
27. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, 
Lu  PC, et  al. Tissue-specific regulatory T cells: biomarker for acute graft-
vs-host disease and survival. Exp Hematol (2012) 40:974–82. doi:10.1016/ 
j.exphem.2012.08.002 
28. Shen X, Du J, Guan W, Zhao Y. The balance of intestinal Foxp3+ regulatory 
T cells and Th17 cells and its biological significance. Expert Rev Clin Immunol 
(2014) 10:353–62. doi:10.1586/1744666X.2014.882232 
10
Shen et al. Tregs Promote Intestinal Allograft Tolerance
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 511
29. Nishio J, Baba M, Atarashi K, Tanoue T, Negishi H, Yanai H, et al. Requirement 
of full TCR repertoire for regulatory T cells to maintain intestinal homeo-
stasis. Proc Natl Acad Sci U S A (2015) 112:12770–5. doi:10.1073/pnas. 
1516617112 
30. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, et al. Direct 
expansion of functional CD25(+) CD4(+) regulatory T cells by antigen-pro-
cessing dendritic cells. J Exp Med (2003) 198(2):235–47. doi:10.1084/
jem.20030422  
31. Xia G, He J, Zhang Z, Leventhal JR. Targeting acute allograft rejection by 
immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory 
T cells. Transplantation (2006) 82:1749–55. doi:10.1097/01.tp.0000250731. 
44913.ee 
32. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regu-
latory T cells synergize with host T-cell depletion to promote long-term 
survival of allografts. Am J Transplant (2008) 8:298–306. doi:10.1111/j.1600- 
6143.2007.02088.x 
33. Sykes M, Szot GL, Swenson KA, Pearson DA. Induction of high levels of 
allogeneic hematopoietic reconstitution and donor-specific tolerance without 
myelosuppressive conditioning. Nat Med (1997) 3:783–7. doi:10.1038/
nm0797-783 
34. Wekerle T, Sykes M. Mixed chimerism and transplantation tolerance. Annu 
Rev Med (2001) 52:353–70. doi:10.1146/annurev.med.52.1.353 
35. Kawai T, Sachs DH, Sprangers B, Spitzer TR, Saidman SL, Zorn E, et  al. 
Long-term results in recipients of combined HLA-mismatched kidney and 
bone marrow transplantation without maintenance immunosuppression. Am 
J Transplant (2014) 14:1599–611. doi:10.1111/ajt.12731 
36. Kean LS, Durham MM, Adams AB, Hsu LL, Perry JR, Dillehay D, et  al. 
A cure for murine sickle cell disease through stable mixed chimerism 
and tolerance induction after nonmyeloablative conditioning and major 
histocompatibility complex-mismatched bone marrow transplantation. 
Blood (2002) 99:1840–9. doi:10.1182/blood.V99.5.1840 
37. Wekerle T, Sayegh MH, Ito H, Hill J, Chandraker A, Pearson DA, et  al. 
Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a 
non-myeloablative conditioning regimen for the induction of mixed hema-
topoietic chimerism and tolerance. Transplantation (1999) 68:1348–55. 
doi:10.1097/00007890-199911150-00022 
38. Joffre O, Gorsse N, Romagnoli P, Hudrisier D, van Meerwijk JP. Induction 
of antigen-specific tolerance to bone marrow allografts with CD4+CD25+ 
T lymphocytes. Blood (2004) 103:4216–21. doi:10.1182/blood-2004-01-0005 
39. Ito H, Takeuchi Y, Shaffer J, Sykes M. Local irradiation enhances congenic 
donor pluripotent hematopoietic stem cell engraftment similarly in irra-
diated and nonirradiated sites. Blood (2004) 103:1949–54. doi:10.1182/
blood-2003-09-3249 
40. Hock K, Mahr B, Schwarz C, Wekerle T. Deletional and regulatory mecha-
nisms coalesce to drive transplantation tolerance through mixed chimerism. 
Eur J Immunol (2015) 45:2470–9. doi:10.1002/eji.201545494 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Shen, Jiang, Yang, Wang, Guan and Du. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License 
(CC BY). The use, distribution or reproduction in other forums is permitted, 
provided the original author(s) or licensor are credited and that the original 
publication in this journal is cited, in accordance with accepted academic practice. 
No use, distribution or reproduction is permitted which does not comply with these 
terms.
